Table 3.
Immunogenicity among participants with underling disease and healthy 14–28 days, 3 months, and 6 months after two-dose vaccination.
| Healthy | CAD | Hypertension | DM | CRD | Obesity | Cancer | |
|---|---|---|---|---|---|---|---|
| Day 14–28 | |||||||
| Seroconversion (%) | 89.00 | 84.00 | 89.00 | 85.00 | 78.00 | 90.00 | 85.00 |
| 95% CIa | (0.84, 0.93) | (0.76, 0.90) | (0.84, 0.93) | (0.79, 0.90) | (0.69, 0.86) | (0.74, 0.98) | (0.76, 0.92) |
| P value | - | 0.1800 | 1.0000 | 0.2900 | 0.0200 | 1.0000 | 0.3400 |
| GMT | 30.50 | 22.77 | 33.89 | 26.45 | 22.44 | 32.92 | 31.96 |
| 95% CIb | (26.41,35.22) | (18.29,28.35) | (29.08,39.49) | (21.99,31.82) | (17.33,29.06) | (20.89,51.88) | (24.00,42.56) |
| P value | - | 0.0300 | 0.3200 | 0.2300 | 0.0400 | 0.7500 | 0.7700 |
| Day 90 | |||||||
| Seroconversion (%) | 55.00 | 52.00 | 58.00 | 52.00 | 51.00 | 65.00 | 61.00 |
| 95% CIa | (0.48, 0.62) | (0.41, 0.64) | (0.50, 0.65) | (0.43, 0.60) | (0.39, 0.63) | (0.44, 0.83) | (0.49, 0.73) |
| P value | - | 0.6900 | 0.6100 | 0.5200 | 0.5800 | 0.4000 | 0.4000 |
| GMT | 8.16 | 6.96 | 8.84 | 7.54 | 7.65 | 8.73 | 9.69 |
| 95% CIb | (7.23,9.20) | (5.73,8.46) | (7.80,10.00) | (6.51,8.73) | (6.15,9.51) | (6.10,12.49) | (7.52,12.49) |
| P value | - | 0.1700 | 0.3600 | 0.4100 | 0.6100 | 0.7200 | 0.2200 |
| Day 180 | |||||||
| Seroconversion (%) | 46.00 | 46.00 | 51.00 | 42.00 | 52.00 | 62.00 | 68.00 |
| 95% CIa | (0.39, 0.53) | (0.35, 0.59) | (0.44, 0.59) | (0.34, 0.50) | (0.40, 0.65) | (0.41, 0.80) | (0.55, 0.79) |
| P value | - | 1.0000 | 0.3100 | 0.5100 | 0.3900 | 0.1500 | 0.0020 |
| GMT | 7.42 | 7.39 | 7.73 | 6.60 | 7.37 | 9.16 | 11.50 |
| 95% CIb | (6.54,8.42) | (5.91,9.24) | (6.66,8.98) | (5.64,7.73) | (5.85,9.28) | (5.87,14.30) | (8.70,15.19) |
| P value | - | 0.9800 | 0.6800 | 0.2500 | 0.9600 | 0.3600 | 0.0050 |
Seroconversion is considered positive when neutralizing antibody titer to live virus is 1:8 or higher.
aEstimated using the Clopper-Pearson method.
bEstimated using the Miettinen-Nurminen method.